

1 **Multi-omic modelling of inflammatory bowel**
2 **disease with regularized canonical**
3 **correlation analysis**

4
5 **Authors:** Lluís Revilla^{1,2}, Aida Mayorgas², Ana Maria Corraliza², Maria C. Masamunt², Amira
6 Metwaly³, Dirk Haller^{3,4}, Eva Tristán^{1,5}, Anna Carrasco^{1,5}, Maria Esteve^{1,5}, Julian Panés^{1,2}, Elena
7 Ricart^{1,2}, Juan J. Lozano¹, Azucena Salas².

8 Corresponding Author: Azucena Salas. Department of Gastroenterology, IDIBAPS, Hospital
9 Clínic 08036, Barcelona, Spain. Phone: +34-932272436 asalas1@clinic.cat

10 1: Centro de Investigación Biomédica en Red de Enfermedades Hepática y Digestivas
11 (CIBERehd), Barcelona, Spain.

12 2: Department of Gastroenterology, IDIBAPS, Hospital Clínic, Barcelona, Spain

13 3: Chair of Nutrition and Immunology, Technical University of Munich, Freising-Weihenstephan,
14 Germany

15 4: ZIEL Institute for Food and Health, Technical University of Munich, Freising-Weihenstephan,
16 Germany

17 5: Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Barcelona, Spain

18

19 **Word count:** 6233

20 **Abbreviations:**

21 IBD: inflammatory bowel disease

22 CD: Crohn's disease

- 23 RGCCA: regularized generalized canonical correlation analysis
- 24 SRGCCA: sparse regularized generalized canonical correlation analysis
- 25 AVE: Average variance explained
- 26 CGH: Comparative genomic hybridization
- 27 HSCT: hematopoietic stem cell transplantation
- 28 SESCD: simple endoscopic score for Crohn's disease

29 **Abstract**

30 **Background**

31 Personalized medicine requires finding relationships between variables that influence a
32 patient's phenotype and predicting an outcome. Sparse generalized canonical correlation
33 analysis identifies relationships between different groups of variables. This method requires
34 establishing a model of the expected interaction between those variables. Describing these
35 interactions is challenging when the relationship is unknown or when there is no pre-
36 established hypothesis.

37 **Aim**

38 To develop a method to find the relationships between microbiome and transcriptome data
39 and the relevant clinical variables in a complex disease, such as Crohn's disease.

40 **Results**

41 We present here a method to identify interactions based on canonical correlation analysis. Our
42 main contribution is to show that the model is the most important factor to identify
43 relationships between blocks. Analysis were conducted on three independent datasets: a
44 glioma, Crohn's disease and a pouchitis data set. We describe how to select the optimum
45 hyperparameters on the glioma dataset. Using such hyperparameters on the Crohn's disease
46 data set, our analysis revealed the best model for identifying relationships between
47 transcriptome, gut microbiome and clinically relevant variables. With the pouchitis data set
48 our analysis revealed that adding the clinically relevant variables improves the average
49 variance explained by the model.

50 **Conclusions**

51 The methodology described herein provides a framework for identifying interactions between
52 sets of (omic) data and clinically relevant variables. Following this method, we found genes and
53 microorganisms that were related to each other independently of the model, while others
54 were specific to the model used. Thus, model selection proved crucial to finding the existing
55 relationships in multi-omics datasets.

56 **Keywords:** Integration, canonical correlation analysis, inflammatory bowel disease, interaction
57 model, machine learning, multi-omics

58 **Declarations**

59 **Ethics approval and consent to participate**

60 The protocol was approved by the Catalan Transplantation Organization and by the
61 Institutional Ethics Committee of the Hospital Clinic de Barcelona. All patients provided written
62 consent following extensive counselling.

63 **Consent for publication**

64 Not applicable.

65 **Availability of data and materials**

66 Analysis code available at: <https://github.com/llrs/TRIM> repository.

67 Parameter studies performed at https://github.com/llrs/sgcca_hyperparameters.

68 Helper package required for the analysis available at <https://github.com/llrs/integration->

69 helper. Package with the methodology:

70 Project name: inteRmodel

71 Project home page: <https://llrs.github.io/inteRmodel/>

72 Operating system: Platform independent

73 Programming language: R

74 License: MIT

75 Data available: glioma data at <https://biodev.cea.fr/sgcca/>.

76 The datasets supporting the conclusions of this article are available in the Gene Expression
77 Omnibus repository, <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139179> (RNA-
78 seq) and <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139680> (microbiome) for
79 the CD dataset and <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65270> for the
80 pouchitis dataset and its additional file(s).

81 **Competing interests**

82 The authors declare that they have no competing interests.

83 **Funding**

84 This work was supported by the Leona and Harry Helmsley Charitable Trust grant 2015PG-
85 IBD005, including the work of AMC, AmM, DH, ET, AC, ME. LLRS, AC, ET, ME and JLL are
86 supported by the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y
87 Digestivas (CIBERehd), AiM by the grant SAF2015-66379-R to AS of the Ministerio de Ciencia,
88 Innovación y Universidades.

89 **Author contributions**

90 LR analyzed the data and wrote the first draft of the manuscript. AiM performed the DNA and
91 RNA extraction and participated in the microbiome analysis. AMC performed the RNA mapping
92 and cleaning. JLL provided guidance and technical assistance. ET, AC and ME recruited the non-
93 IBD patients for the study. JP, ER, recruited IBD patients for the study. AS selected the clinically
94 relevant variables, provided guidance on model selection and data interpretation and
95 corrected the manuscript. MC contributed to samples processing. DH and AmM performed the
96 microbiome sequencing. All authors read and approved the submitted manuscript.

97 **Acknowledgements**

98 We thank Daniel Aguilar for RNA-seq analysis assistance and Ilias Lagkouvardos for his
99 assistance on 16S-seq analysis. We are grateful to Joe Moore for English-language assistance.

100 **Authors' information**

101 LR: lrevilla@clinic.cat Centro de investigación biomédica y en Red. Enfermedades Hepáticas y
102 Digestivas, CIBERehd. Department of Gastroenterology, IDIBAPS, Hospital Clínic, Barcelona,
103 Spain. ORCID: <https://orcid.org/0000-0001-9747-2570>

104 AiM: mayorgas@clinic.cat Department of Gastroenterology, IDIBAPS, Hospital Clínic,
105 Barcelona, Spain. ORCID: <https://orcid.org/0000-0003-4467-5352>

106 AMC: corraliza@clinic.cat Department of Gastroenterology, IDIBAPS, Hospital Clínic,
107 Barcelona, Spain. ORCID: <https://orcid.org/0000-0002-3067-7763>

108 MCM: mmasamun@clinic.cat Department of Gastroenterology, IDIBAPS, Hospital Clínic,
109 Barcelona, Spain.

110 AmM: amira.metwaly@tum.de Chair of Nutrition and Immunology, Technical University of
111 Munich, Freising-Weihenstephan, Germany. ORCID: <https://orcid.org/0000-0001-5740-0230>

112 DH: dirk.haller@tum.de Chair of Nutrition and Immunology, Technical University of Munich,
113 Freising-Weihenstephan, Germany. ZIEL Institute for Food and Health, Technical University of
114 Munich, Germany ORCID: <https://orcid.org/0000-0002-6977-4085>

115 ET: etristan@mutuaterrasa.cat Department of Gastroenterology, Hospital Universitari Mútua
116 Terrassa, CIBERehd, Barcelona, Spain

117 AC: anna.carrasco.garcia@gmail.com Department of Gastroenterology, Hospital Universitari
118 Mútua Terrassa, CIBERehd, Barcelona, Spain. ORCID <https://orcid.org/0000-0001-8810-1583>

119 ME: mariaesteve@mutuaterrassa.cat Department of Gastroenterology, Hospital Universitari
120 Mútua Terrassa. CIBERehd, Barcelona, Spain

121 JP: jpanes@clinic.cat Department of Gastroenterology, IDIBAPS, Hospital Clínic, Barcelona,
122 Spain. ORCID <https://orcid.org/0000-0002-4971-6902>

123 ER: ericart@clinic.cat Centro de investigación biomédica y en Red. Enfermedades Hepáticas y
124 Digestivas, CIBERehd. Department of Gastroenterology, IDIBAPS, Hospital Clínic, Barcelona,
125 Spain. ORCID: <https://orcid.org/0000-0003-3354-1594>

126 JLL: juanjo.lozano@ciberehd.org Bioinformatics Platform, Centro de Investigación Biomédica
127 en Red de Enfermedades Hepática y Digestivas (CIBEREHD), Barcelona Catalonia, Spain.
128 ORCID: <https://orcid.org/0000-0001-7613-3908>

129 AS: asalas1@clinic.cat Corresponding author, Department of Gastroenterology, IDIBAPS,
130 Hospital Clínic, Barcelona, Spain. ORCID: <https://orcid.org/0000-0003-4572-2907>

131

132 **Background**

133 The creation of datasets from different high-throughput sequencing technologies on the same
134 samples provides an opportunity to identify relationships between datasets and improve our
135 understanding of diseases. This approach has been used in several diseases, such as cancer,
136 inflammatory bowel disease (IBD) and pouchitis, among others [1–3].

137 IBD is comprised of Crohn’s disease (CD) and ulcerative colitis (UC). Around 4.2 million
138 individuals suffer from IBD in Europe and North America combined [4]. The chronic
139 inflammatory response observed suggests an interaction between host genetic factors and the
140 intestinal microbiota. Several studies support the concept that CD arises from an exacerbated
141 immune response against commensal gut microorganisms in genetically predisposed
142 individuals. Nonetheless, the disease might result from imbalanced microbial composition,
143 leading to dysbiosis [5, 6].

144 Understanding the contribution of the gut microbiota to CD pathogenesis and maintenance of
145 the disease is an ongoing field of research [7–9]. These alterations could be shaped by a
146 genetic predisposition and environmental factors (i.e., bacterial or viral infection, diet, usage of
147 antibiotic, or the socioeconomic status) [10]. Pouchitis is the inflammation of the ileal pouch,
148 an artificial rectum surgically created out of ileal gut tissue in patients who have undergone a
149 colectomy. One possible underlying cause of pouchitis might be the microbiome [11].

150 However, the cause-effect relation between dysbiosis and intestinal inflammatory disease
151 remains unclear [12–14].

152 The most common method for analyzing the relationship between microorganisms and the gut
153 mucosa is to sequence both the 16S rRNA gene of the microbiome and the patient’s
154 transcriptome using DNA and human RNA, respectively, both extracted from the same sample.
155 In some cases, patients are followed up for long periods and longitudinal samples can be

156 obtained [15]. Multiple omics have been increasingly used to identify relationships between
157 the intestinal microbiome and gut epithelium using a variety of methods [8, 14, 16, 17].

158 Both univariate and multivariate methods are used to analyze DNA and RNA data. Some
159 methods find relationships between the human transcriptome and the gut microbiome
160 composition. Correlations, which are multivariate, are the predominant method used to find
161 relationships between two omics datasets [7, 17–19]. A recent study revealed more significant
162 correlations in samples from healthy controls than in patients with IBD, and suggests an
163 “uncoupling” of the microbiota from homeostasis [7]. Although their analysis used
164 correlations, as well as univariate methods, these method do not consider confounders such as
165 age, diet or sample localization in the gut, all of which could lead to false conclusions [20, 21].

166 Other multivariate methods provide frameworks with an unlimited number of variables
167 involved. These multivariate methods summarize the variability of the datasets and select
168 features in order to obtain loading factors for a new coordinate system. They aim to
169 summarize the largest amount of variability found among the samples’ variables [22]. Multi-
170 block methods are multivariate methods capable of summarizing several variables from the
171 same sample, but corresponding to different technical origins [23–27]. These multi-block
172 methods assume the existence of relationships between variables of the different blocks.

173 Regularized generalized canonical correlation analysis (RGCCA) is a multi-block method that
174 enables reducing the dimensions of an arbitrary number of blocks for data derived from the
175 same sample [28–30]. RGCCA has already been used in the context of IBD with RNA-seq and
176 16S rRNA data [16]. However, it was used to select variables related to the inflammation
177 predictors DUOX2 and APOA1. To our knowledge, a concrete description of the relationship
178 between the gut’s mucosal transcriptome and microbiome in CD using RGCCA has not been
179 performed.

180 In this study, we evaluate the effect of the parameters of RGCCA and we identify a strategy of
181 analysis that better explains a previously published glioma cohort to validate the method [31].
182 We then applied this method to our CD dataset and to a pouchitis cohort in order to identify
183 interactions between microorganisms and the transcriptome of the gut epithelium [32]. We
184 believe that this approach is crucial to find the various relationships in multi-omics datasets
185 and select the most relevant variables.

186 **Methods**

187 **Patients and biopsies processing**

188 Samples from the CD cohort included in this study were from patients treated in the
189 Department of Gastroenterology (Hospital Clínic de Barcelona – Spain –) all of whom signed a
190 consent form. A cohort of patients with severe refractory CD that underwent hematopoietic
191 stem cell transplant (HSCT). Colonic and ileal biopsies were obtained at several time points
192 from CD patients undergoing routine colonoscopies. Patients were followed-up for 4 years and
193 samples were collected every six or twelve months after HSCT. Samples were collected from
194 both uninvolved and involved areas. In addition, biopsies were taken from the ileum and colon
195 of 19 non-IBD patients consisting of individuals with no history of IBD who had no significant
196 pathological findings following endoscopic examination for colon cancer surveillance (Hospital
197 Univesitari Mútua de Terrassa – Spain –). At least one biopsy was fresh-frozen at -80°C for
198 microbial DNA extraction. The remaining biopsies were placed in RNAlater RNA Stabilization
199 Reagent (Qiagen, Hilde, Germany) and stored at -80°C until total RNA extraction.

200 **Mucosal transcriptome**

201 Total RNA from mucosal samples was isolated using the RNeasy kit (Qiagen, Hilde, Germany).
202 RNA sequencing was performed as previously described [15]. Analysis was performed using
203 an R version (3.6.1) statistical tool and Bioconductor (Version 3.9) on Ubuntu 18.04. The

204 transcriptome was visually inspected for batch effects in PCA. Outliers and the top 10% genes
205 using the coefficient of variation were removed. Data was normalized using the trimmed mean
206 of M-values and log transformed into counts per millions using edgeR (version 3.26).

207 **Microbial DNA extraction from mucosal samples**

208 Biopsies were resuspended in 180 μ l TET (TrisHCl 0.02M, EDTA 0.002M, Triton 1X) buffer and
209 20mg/ml lysozyme (Carl Roth, Quimivita, S.A.). Samples were incubated for 1h at 37°C and
210 vortexed with 25 μ l Proteinase K before incubating at 56°C for 3h. Buffer B3 (NucleoSpin
211 Tissue Kit – Macherey-Nagel) was added followed by a heat treatment for 10 min at 70°C. After
212 adding 100% ethanol, samples were centrifuged at 11000 x *g* for 1 min. Two washing steps
213 were performed before eluting DNA. Concentrations and purity were checked using NanoDrop
214 One (Thermo Fisher Scientific). Samples were immediately used or placed at -20°C for long-
215 term storage.

216 **High throughput 16S ribosomal RNA (rRNA) gene sequencing**

217 Library preparation and sequencing were performed at the Technische Universität München as
218 described in detail previously [33]. Briefly, the V3-V4 regions of the 16S rRNA gene were
219 amplified (15x15 cycles) following a previously described two-step protocol [34] using forward
220 and reverse primers 341F-785R [35]. Purification of amplicons was performed by using the
221 AMPure XP system (Beckmann). Next, sequencing was performed with pooled samples in
222 paired-end modus (PE275) using an MiSeq system (Illumina, Inc.) according to the
223 manufacturer's instructions and 25 % (v/v) PhiX standard library.

224 **Microbial profiling**

225 Data analysis was performed as previously described [36]. Processing of raw-reads was
226 performed by using the IMNGS pipeline based on the UPARSE approach [37]. Sequences were
227 demultiplexed, trimmed to the first base with a quality score <3 and then paired. Sequences

228 with less than 300 and more than 600 nucleotides and paired reads with an expected error >3
229 were excluded from the analysis. Trimming of the remaining reads was done by trimming 5
230 nucleotides from each end to avoid GC bias and non-random base composition. Operational
231 taxonomic units (OTUs) were clustered at 97% sequence similarity. Taxonomy assignment was
232 performed at 80% confidence level using the RDP classifier [38] and the SILVA ribosomal RNA
233 gene database project [33]. The microbiome was visually inspected for batch effects in PCA;
234 none were found. The resulting OTUs table was normalized using edgeR.

235 **The glioma dataset**

236 We used a previously published dataset with 53 samples from glioma patients that included
237 the transcriptome, copy number variation, and data from comparative genomic hybridization
238 (CGH). This dataset contained information about age, localization of the tumor, sex and a
239 numerical grading of the severity of the tumor (See Table 1) [31, 39].

240 **The Crohn's disease dataset**

241 Samples that had both RNA and microbial DNA corresponding to the same patient were
242 included. In total, 158 samples were used for the integration, including those from 18 patients
243 with CD and 19 non-IBD controls (See Table 1). In addition to the samples, clinical information
244 such as age, sex, treatment, years since disease diagnosis, prior surgery, location of the
245 biopsies, segmental simple endoscopic score for Crohn's disease (SESCD), time of the
246 transplant and response to treatment were collected.

247 **The pouchitis dataset**

248 A previously published dataset of pouchitis was downloaded containing gene expression data
249 from 273 samples and 16S data on the microbiome presence (See Table 1)[32]. This dataset
250 contained identifiers for the patients, whether the sample was from the pre-pouch ileum or
251 from the pouch, the sex, the outcome of the procedure and an inflammatory severity score

252 ISCORE. A total of 255 samples from 203 patients were used with data for both transcriptome
 253 and microbiome.

254 **Table 1: Summary of samples and characteristics of the datasets used.**

	Glioma	CD	Pouchitis
Samples (non-disease /diseased)	0/53	51/107	0/255
Sex (female/male)	28/25	22/15	101/102
Location	Cort: 20	Ileum: 48	Pouch: 59
	Dipg: 22	Colon: 108	PPI: 196
	Midl: 11	Unknown: 2	
SESCD local (mean (min-max))	NA	2.15 (0-12)	NA
CDAI mean (min-max)	NA	120 (0-450)	NA
Age at diagnostic (<16/16<x<40/x>40 years)		7/11/0	
Years of disease: mean (min-max)		14 (8-28)	

255 PPI: pre-pouch ileum. Cort: supratentorial, midl: central nuclei, dipg: brain stem. NA not applicable; an empty cell
 256 signifies unknown.

257 **Integration**

258 Sparse regularized generalized canonical correlation analysis (SRGCCA), implemented in RGCCA
 259 package (version 2.12), was used for this integration [40]. This variation of the RGCCA method
 260 is better suited for biological data with sparsity such as the results obtained by RNA
 261 sequencing. The scheme used to add the different canonical components was the centroid
 262 scheme, which allows one to determine the positive and negative related variables. The
 263 regularization parameters used were those suggested by the tau.estimate, which is a
 264 compromise between correlation and covariance [41]. When looking for the covariance from
 265 phenotypic categorical variables, one was used for regularization in order to maximize the
 266 covariance instead of the correlation.

267 Numeric values from the same assay were set on the same block. Relevant clinical variables
268 were grouped in one block unless otherwise indicated. Categorical data was encoded as binary
269 (dummy) variables for each factor, where 0 indicates not present and 1 present. Each block
270 was standardized to zero mean and unit variances, and then divided by the square root of the
271 number of variables of the block with the function `scale2`.

272 **Hyperparameters testing**

273 The sparse canonical correlation analysis has three hyperparameters: the regularization
274 parameter, tau, the model and the scheme. To evaluate the effect of each hyperparameter,
275 the parameter being tested was changed while keeping constant all the other parameters. This
276 model includes weights indicating the relationship between the blocks.

277 All models were analyzed using weights from 0 to 1 in the relationship between blocks. To test
278 the effect of the model, all combinations of weights were tested. The inner AVE was used to
279 select the best model. Inner average variance explained (AVE) is defined by how well the
280 components of each block correlate with each other [29].

281 The scheme controls how the different correlations of the canonical components are
282 summarized. The three schemes available (horst, centroid and factorial) are compared
283 regarding their inner AVE and the selected genes using a simple model.

284 The regularization parameter, tau, was tested between the minimum accepted value for each
285 block and one for each block of the glioma dataset.

286 Models were validated using 1000 bootstraps with resampling to assess the stability of the
287 inner and outer AVE. Outer AVE is defined by the correlation between the variables of a block
288 and the component of the block [29].

289 **Models used**

290 Different models were tested for integration with the same data of the CD and pouchitis
 291 dataset. The first model, model 0, used only two blocks, the microbiome and the
 292 transcriptome data with interaction between them and with no within interactions (Model not
 293 shown).

294 The second family of models (models 1, 1.1 and 1.2; see Table 2), in addition to the
 295 microbiome and transcriptome data, used the clinically relevant variables including some that
 296 were related to disease activity. For instance, the CD dataset included the following variables:
 297 patient ID, sex, age, age at diagnosis, surgery, treatment, time after transplant and location of
 298 the sample.

299 **Table 2: Table representing the family of type 1 models.**

	Transcriptome	Microbiome	Variables
Transcriptome	0	[0-1]	[0-1]
Microbiome	[0-1]	0	[0-1]
Variables	[0-1]	[0-1]	0

300 [0-1] indicates that the relation between the blocks has been tested at several weights between 0 and 1.

301 **Table 3: Table representing the type 2 family of models for the CD dataset.**

	Transcriptome	Microbiome	Sample	Location	Time
Transcriptome	0	[0-1]	[0-1]	[0-1]	[0-1]
Microbiome	[0-1]	0	[0-1]	[0-1]	[0-1]
Sample	[0-1]	[0-1]	0	[0-1]	[0-1]
Location	[0-1]	[0-1]	[0-1]	0	[0-1]
Time	[0-1]	[0-1]	[0-1]	[0-1]	0

302 The same data of the variables block based on the family model 1 is split into 3 additional blocks. [0-1] indicates that
 303 the relation between the blocks has been tested at several weights between 0 and 1.

304 The last family of models (models 2, 2.1, 2.2 and 2.3) used the same information as that for
305 type 1 models, but grouped the clinical variables into three blocks, one for demographics, one
306 for time-related variables and one for variables related to localization of the sample (Table 3).
307 Models 1 to 2.3 were modeled to utilize known, clinically relevant variables with the
308 transcriptome and microbiome data available.

309 With the glioma dataset, the microbiome block was replaced by the CGH block. In addition to
310 the previously mentioned models, the glioma dataset was also analyzed considering all the
311 variables from the different blocks as a single entity, which is known as a superblock [42].

312 Only the models in which all the blocks were part of a single connected network were
313 analyzed. For models 1 to 2.3, all the combinations of different weights on the model matrix
314 were analyzed. First weights 0, 0.5 and 1 were used to select the model with the highest inner
315 AVE. To further accurately describe the interactions of models 1.1 and 2.1, different weights
316 from 0 to 1 by 0.1 were tested; the best one resulted from model 1.2 and 2.2, respectively. The
317 higher the AVE is, the better the model is. A direct interaction between the microbiome and
318 the transcriptome was used to check if the results of model 2.2 had improved in model 2.3.


319 **Results**

320 The effects of the hyperparameters on SRGCCA were first evaluated on the glioma dataset
321 (glioma dataset, Table 1) [31]. Once we had determined the effect of each hyperparameter, we
322 integrated the two different datasets. First, we looked for the relationship between the
323 transcriptome and the microbiome in biopsy samples from patients with CD undergoing HSCT
324 (CD dataset, Table 1). Second, we studied the microbial relationships with the transcriptome in
325 a previously published pouchitis cohort (pouchitis dataset, Table 1) [32]. Then we compared
326 the models on each dataset for robustness.

327 **Hyperparameters on the glioma dataset**

328 We first analyzed the best strategy to find the right values of the hyperparameters on SRGCCA
329 on the glioma dataset. By hyperparameters we mean the scheme used, the regularization
330 effect, and the models as constructed by weights, all of which can affect the final solution of
331 the SRGCCA.

332 The regularization parameter, also called tau, controls the number of variables selected by
333 each block. Tau can be estimated by using Schäfer's method [41], which tries to conserve both
334 the correlation and the covariance. When estimated by this method, the tau provides a good
335 intermediate solution for numeric variables. For those blocks that encode categorical variables
336 as numeric values, it is more relevant the covariance; thus, a tau value of 1 was used. The
337 effect of tau on the inner AVE is shown in Fig. 1.




338

339 **Fig. 1** Regularization effect of the inner AVE for the same model on the glioma dataset. Each
340 point is the result of an SRGCCA with different tau values for each block (GE as the
341 transcriptome, CGH (comparative genomic hybridization) for the copy number variation and y
342 for the location).

343 All of the weights between 0 and 1 (by 0.1) in the glioma dataset were analyzed using all three
344 schemes: horst, centroid and factorial. The horst and the centroid scheme were similar while
345 the factorial resulted in the most different AVE values (see Additional file 1). The centroid
346 scheme was selected because it took into account all the relationship regardless of the sign of
347 the canonical correlation, and because of its similarity to horst.

348 The three blocks with the best tau and the centroid scheme were analyzed by tuning the
349 weights. According to the inner AVE, the best model was that in which the weights between
350 the transcriptome and location, the transcriptome and the CGH, and the CGH block were
351 linked to variables related to the location with weights of 1, 0.1 and 0.1, respectively.

352 When we added a superblock to the data, there was an increase of 0.01 on the inner AVE of
353 the model. The model with the superblock that explained most of the variance was that in
354 which the weights of the interaction within the transcriptome, between the superblock and
355 the CGH, between the transcriptome and the localization, and between CGH and
356 transcriptome were 1, 1, 1 and 1/3, respectively. Fig. 2 shows the first two components of the
357 superblock.




358

359 **Fig. 2 First two dimensions of the superblock on the glioma dataset.** The first two
360 components of the superblock with the best model, according to the inner AVE from the
361 glioma dataset. Each point is a sample (colored by location) signifying the following Cort:
362 supratentorial, dipg: brain stem, midl: central nuclei. The locations of the samples could not be
363 determined by the position of the samples on these components

364

365 Adding to the model one block containing the age of the patient and the severity of the tumor
366 decreased the inner AVE. The best model with these blocks, according to the inner AVE, was
367 that in which the interactions within transcriptome, between the transcriptome and the
368 localization, between the transcriptome and the CGH and between the CGH and the other
369 variables were 1, 1, 1/3 and 1/3, respectively (See additional file 2, Glioma's sheet). The first
370 components of each model can be seen in Fig. 3:



371

372 **Fig. 3 First dimensions of the transcriptome and the CGH block of models on the glioma**

373 **dataset.** Comparison of the different models by visualizing the first components of the

374 transcriptome (GE) and the copy number variation (CGH) blocks from the glioma dataset. Each

375 point represents a sample (colored by location). Cort: supratentorial, dipg: brain stem, midl:

376 central nuclei.

377 Here, one can see that the tau value proposed by Schäfer's method is a good approximation of

378 the optimum value for the data and can be used in the other datasets containing omics data.

379 As the model with a superblock did not help explain the relationships between blocks, it could


380 not be used in the other datasets. The scheme selected was the centroid, which takes the

381 absolute value of the relation between components. These hyperparameters were used for

382 further analysis on the CD and pouchitis datasets.

383 **Analyzing the models on the CD and pouchitis datasets**

384 Each dataset has different relationships that should be taken into account when looking for
385 relationship on the dataset. The CD dataset (see Table 1) was analyzed with SRGCCA. The
386 samples are shown on the first components of the microbiome and the transcriptome **Error!**
387 **Reference source not found.Fig. 4**). The first canonical components for the microbiome and
388 the expression data for all of the models facilitated the classification of the samples according
389 to the sample location (ileum or colon) or disease status (CD or control).



390 **Fig. 4 First dimensions of the transcriptome and the microbiome block of models on the CD**
391 **dataset.** Comparison of the models that better explained the interaction between the
392 microbiome and the transcriptome data on the CD dataset. Each point represents a sample
393 (colored by disease status): A, non-CD (Control) or CD; and B, by location, colon or ileum, on
394 the first components of the transcriptome and the microbiome.


395

396 Model 1.2 had the highest inner AVE of the family 1 model. A search for the highest inner AVE
397 within the family 2 models resulted in model 2.2, which revealed a direct relationship between

398 the transcriptome and the location-related variables, while the microbiome was associated
399 with the demographic and location-related variables.


400 The pouchitis dataset (See Table 1) was analyzed and the samples are shown on the first

401 components of the microbiome and the transcriptome in



402

403 Fig. 5.



404

405 **Fig. 5 First dimensions of the transcriptome and the microbiome block of models on the**
406 **pouchitis dataset.** Comparison of the models vis-a-vis the pouchitis dataset by the first
407 component of the transcriptome and the microbiome from the CD dataset. Each point
408 represents a sample colored by sex (A), where females are in red and males in blue, and by
409 location (B), where the pouch is the red, and PPI is the pre-pouch ileum

410

411 Model 1.2 had the highest inner AVE. A search for the highest inner AVE among the family 2
412 models resulted in model 2.2, although it does not have the highest inner AVE. Moreover, no
413 direct relationship between the transcriptome and the clinically relevant variables was
414 apparent (See additional file 3). Family 2 models better stratified the samples by location than
415 did those of family 1.

416 In the CD dataset we see that the relationships evident in the model affected the distribution
417 of samples on the components of both the transcriptome and the microbiome. We found that
418 model 2.2 best stratified the disease status and locations of the samples. Other models
419 grouped the samples by disease status and location based on how close the model was to the
420 weights associated with model 2.2. In all of the models we observed associations between the
421 disease status and the microbiome and the sample location with the transcriptome.

422 With the pouchitis dataset no stratifications by sex were similarly apparent to that observed in
423 the CD dataset. Nonetheless, they were separated by location-related variables in some
424 models, albeit not as clearly as with the CD dataset. This might indicate that while sex does not
425 affect the interaction, the location-related variables do affect the pouchitis.


426 **Comparison of models in Crohn's disease and the pouchitis dataset**

427 The same dataset with different models results in different relevant variables. With the CD
428 dataset we looked for the best model using a single block for the clinically relevant variables,
429 following the family model 1 structure. The family 1 model with the highest AVE was that in
430 which the transcriptomics was related the phenotype by 0.1, while the microbiome was
431 related to the clinically relevant variables by 1. This model revealed that the relationship
432 between the microbiome and the clinically relevant variables carried more weight than that
433 between the clinically relevant variables and the transcriptomics on the CD dataset.

434 The best model according to the inner AVE score on the CD dataset was model 2.2. In this
435 model, the transcriptome was related to location-related variables by a weight of 1, while the
436 microbiome was related to demographic variables, and to location related variables, by a
437 weight of 1 and 0.5, respectively. Demographic variables were also linked by 1 to the time
438 variables block (See additional file 2, CD's sheet).

439 The interaction of genes within the transcriptome was also analyzed on the CD dataset. It
 440 increased the inner AVE score between 0.10 and 0.03 depending on the model. However, it
 441 was not deemed important to find the relationships between the transcriptome and the
 442 microbiome and thus was not compared between datasets.

443 In order to analyze the accuracy of the models, one thousand bootstraps were used to
 444 integrate the data from the CD dataset (see Fig. 6 and Table 4 below).



445

446 **Fig. 6 Bootstrap results of three models on the CD dataset.** Variance of AVE using the same
 447 samples on three models with the CD dataset. Each point shows the AVE for each analysis
 448 performed. The brighter colors reflect the result of this model on the original data (including
 449 all samples).

450

451 Model 2.2 had both higher inner and outer AVE mean values and less standard deviation (Fig. 6
 452 and Table 4). This indicates that it was more robust than the other models, regardless of the
 453 input data.

454 **Table 4: Bootstrapped mean and standard deviation of inner and outer AVE values on the CD dataset.**


Model	AVE	Mean	Sd
-------	-----	------	----

0	inner	0,550	0,0469
1.2	inner	0,768	0,0223
2.2	inner	0,785	0,0163
0	outer	0,104	0,0132
1.2	outer	0,088	0,0106
2.2	outer	0,105	0,0069

455 The best models according to the mean are shown in bold.

456 On the other hand, the model with the highest inner AVE on the pouchitis dataset was model
457 1.2, which included a relationship between the microbial data and the transcriptome of 0.1, as
458 well as a relationship between the microbial data and the metadata of 1 (See additional file 2,
459 Pouchitis' sheet). Other models from family 2 had less AVE. The family 2 model with a higher
460 inner AVE was model 2.2. The first dimension of the transcriptome separates by location on
461 models of family 2 while the first component of the microbiome doesn't separate by males and

462 females (See



463

464 Fig. 5).

465 The bootstrap analysis of the one thousand bootstraps on the pouchitis dataset showed that
 466 model 1.2 had the highest mean inner AVE, although model 0 had the highest mean outer AVE
 467 (See Table 5). As the mean outer AVE for model 1.2 was close to model 0, the former was
 468 considered the most robust.

469 **Table 5 Bootstrapped mean and standard deviation of inner and outer AVE values on the pouchitis dataset.**

Model	AVE	Mean	Sd
-------	-----	------	----

0	inner	0,448	0,0811
1.2	inner	0,820	0,0457
2.2	inner	0,767	0,0332
0	outer	0,140	0,0087
1.2	outer	0,120	0,0227
2.2	outer	0,134	0,0085

470 The models with the higher mean AVE values are shown in bold.

471 The models with the highest inner AVE were more robust to different data, which indicates
472 that they can be applied more generally and not solely to these samples.

473 **Discussion**

474 This study provides a framework for identifying interactions between blocks of data, a step
475 towards understanding biological relationships between datasets or between datasets and
476 other particularly relevant variables. First, we studied the hyperparameters' influence on a
477 glioma dataset, adjusting their values. Then, we developed a method to find the best model
478 for the relationships between blocks. Lastly, we validated the method in two independent
479 cohorts.

480 We explored the regularization of the blocks on the glioma cohort. The regularization of a
481 block modulates how many variables are selected [26, 28]. The use of tau 1 allowed us to
482 select all variables, which maximized the covariance of the variables. On blocks that included
483 only clinically relevant categorical variables, regularization must be equal to 1. As the
484 transcriptome and microbiome blocks contain many variables, a shrinkage parameter close to
485 0 was expected, as was observed with the glioma and other cohorts. In addition, estimating
486 tau for the quantitative blocks resulted in higher inner AVE scores since the quantitative
487 variables that contributed most to the data variation were selected.

488 Based on the regularization obtained, we explored different schemes of integration on the
489 glioma cohort. The resulting canonical components of the centroid and horst schemes did
490 differ in some models. In fact, the canonical correlations between blocks was likely positive,
491 making the differences between these two schemes unobservable. The centroid scheme was
492 selected to analyze the CD and the pouchitis datasets, since canonical correlations are not
493 always positive.

494 Independently of the scheme involved, a superblock not only aids in interpretation, but also
495 helps account for the possibility of interactions between variables of the same block. The
496 increase observed in the inner AVE may have stemmed from the interaction between variables
497 of the same block. However, such an interpretation is not as clear as with blocks generated by
498 a single assay or from closely related variables [28]. The superblock, which is used for
499 redundancy analysis, did not help in terms of grouping different samples [42]. Moreover, if the
500 goal of the model is to accurately represent the system under study, the superblock is not
501 necessary, regardless of the assistance it provides in improving the inner AVE.

502 The superblock is usually related to all the other blocks. Typically, a weight of 1 is used to
503 indicate a direct relationship between two blocks. Modifying the weights of the model
504 influenced the result by changing AVE scores and the variables selected from each block. The
505 highest inner AVE score was not defined by the highest weights on all the relationships.

506 The weights of the models represent how much one block interacts with another if the
507 interactions are linear, an assumption of any canonical correlation [29]. In such cases, the
508 weights are representative of the interactions between blocks.

509 The weights define the relationships between blocks in SRGCCA, which together determine the
510 model of the components. Other methods like MCIA and JIVE assume a common relationship
511 between all components, which results in a common space for the samples [25, 26]. This
512 difference is crucial for exploring the role of the components; for example, in this paper each

513 model represents the same system with different interactions and assumptions. Comparing
514 different models after the SRGCCA led to explanations for different aspects of the same
515 system.

516 Looking at the glioma data, the best model according to the inner AVE was that with the
517 superblock. As previously explained, this model might represent the hierarchical relationships
518 present in the data. However, the superblock did not provide more interpretable results in the
519 glioma dataset.

520 In the glioma cohort, the model lacking the superblock but with the highest inner AVE
521 indicated that the localization of a tumor influences the transcriptome to a greater degree
522 than the copy number variations, if the relationships are linear. Adding additional information
523 on the samples' localization origin did not increase the inner AVE, suggesting that there was a
524 high dependence between localization and the tumor transcriptome.


525 Interactions within the transcriptome usually increase the inner AVE of the models. With the
526 CD and the pouchitis datasets, self-interaction increased the inner AVE, as well as the selected
527 features, except in models 0 to 1.2 in the CD data set. This suggests that the interactions within
528 the same omic block become relevant if the model does not take into account the interaction
529 between other clinically relevant variables. If other relevant variables are included, then the
530 effect of this interaction is significantly less.

531 Model 0 looked for direct relationships between the microbiome and the transcriptome.
532 Confounders that influence both transcriptome and microbiome, such as age or the
533 localization and inflammation status, were not taken into account in this model. This is due to
534 the fact that they can bias the relations found with this model [43]. Nonetheless, this model
535 was capable of grouping the samples of the CD cohort according to their disease status,
536 though this was not true of the pouchitis dataset.

537 Family 1 models use three blocks, including one for clinically important information about the
538 samples. This new block was added to avoid biasing the integration by known factors of the
539 samples. In the best model of this family, the microbiome block had a weak relationship with
540 the transcriptome. This weak relationship was possibly indicative that the relations were not
541 lineal. If the relationships were not lineal, then they could not be fully identified by RGCCA
542 [29]. Another possibility is that the microbiome was related to other variables not included on
543 the dataset.


544 Finally, family 2 models, compared to those of family 1, were designed to explain the
545 relationship between the microbiome and transcriptome, allowing for the presence of
546 independent interactions with location, age and other demographic-related variables. In family
547 1 models all the relevant variables were mixed together. In order to allow for such
548 interactions, unrelated variables were separated in different blocks. Genes selected by SRGCCA
549 proved different between the family 1 and 2 models (see Fig. 7), suggesting that the
550 relationship between microorganisms and genes was heavily influenced by location, time and
551 demographic-related variables (see Fig. 8).

552



553

554 **Fig. 7 UpSet plot of the genes shared between models on the CD dataset.** The heights of the
 555 bars represent the genes shared between the models selected by the points; 30 intersections
 556 are shown. The lengths of the horizontal bars represent the selected genes in each model.



557

558 **Fig. 8 UpSet plot of the microorganisms selected by the models on the CD dataset.** The
 559 heights of the bars represent the OTUs shared between the models selected by the points; 30
 560 intersections are shown. The lengths of the horizontal bars represent the selected OTUs in
 561 each model.

562

563 Of all these models, the best according to the inner AVE on the CD dataset was model 2.2. This
 564 model showed known differences between the transcriptome in the gut regions [15]. The
 565 microbiome separated the samples by disease status, indicating that it was highly relevant for
 566 the relationship with the transcriptome. In addition, the dispersion of mean average variance
 567 was reduced as more complex models were used, as can be seen in Fig. 6, indicating that they
 568 were more robust to different data.

569 In the CD dataset, a cursory analysis confirmed that the genes selected by SRGCCA with model
570 2.2 were related to the sample location [15]. Among the selected microorganisms previously
571 linked to CD dysbiosis on this list were *Faecalibacterium sp.* and *Bacteroides sp.* (see Additional
572 file 4)[44]. This suggests that the variables selected were relevant for their role in both the
573 tissue and the disease. Thus, the genes and microorganisms that have significant relationships,
574 in this context, were likely to be present.

575 In the pouchitis dataset, model 1.2 captured a greater degree of variance than model 2.2,
576 contrary to the results obtained with the CD dataset. This might be because potentially
577 important variables, such as age, were lacking and possibly because the model was
578 confounded. In addition, we could not make direct comparisons with the CD dataset as it did
579 not include non-diseased samples. This is due to the fact that the model differentiates by
580 subgroups of patients instead of by a distinct relationship between healthy and diseased
581 samples.

582 The findings of this study have to be assessed in light of certain limitations. RGCCA can not
583 describe a causal relationship or the mechanisms underlying the relationships between RNA
584 transcriptomics and the microbiome. However, models for RGCCA can be used to select
585 variables for further studies and experiments in order to validate these relationships.

586 When examining an interaction within a block, we only assumed the existence of an
587 interaction within the transcriptome. However, it must be noted that microorganisms create
588 communities for which the interactions of several microorganisms is essential and we did not
589 consider interaction within the microbiome in the present study [45]. Knowing how microbial
590 communities rise and interact remains an open question that could affect any interpretation of
591 the results [45, 46].

592 In the present study, as we did not use a simulated data set with known relationships between
593 blocks, we could not assess the specificity or sensitivity of our approach. In addition, we did not

594 confirm by further analysis and experiments whether the selected variables were necessary to
595 start or maintain CD or pouchitis.

596 **Conclusions**

597 RGCCA is a powerful integration tool. We have shown that the model is the most important
598 parameter when selecting variables. The weights of the model represent the strengths of the
599 relationships between blocks. Here we propose a robust methodology to identify the best
600 models guided by the inner AVE when there is no prior knowledge of the existing relationship.
601 This method can identify relationships in complex systems such as Crohn's disease by taking
602 into account the interactions between the microbiome, transcriptome and the relevant clinical
603 variables. The resulting analysis can improve our understanding of the biological relationships
604 between different omics datasets and other relevant (clinical) variables.

605 **References**

- 606 1. Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an
607 immeasurable source of knowledge. *Contemp Oncol Poznan Pol.* 2015;19:A68-77.
- 608 2. Human Microbiome Project Consortium BA, Nelson KE, Pop M, Creasy HH, Giglio MG,
609 Huttenhower C, et al. A framework for human microbiome research. *Nature.* 2012;486:215–
610 21. doi:10.1038/nature11209.
- 611 3. Beale DJ, Karpe AV, Ahmed W. Beyond Metabolomics: A Review of Multi-Omics-Based
612 Approaches. In: Beale DJ, Kouremenos KA, Palombo EA, editors. *Microbial Metabolomics:
613 Applications in Clinical, Environmental, and Industrial Microbiology.* Cham: Springer
614 International Publishing; 2016. p. 289–312. doi:10.1007/978-3-319-46326-1_10.
- 615 4. Holmberg FE, Seidelin JB, Yin X, Mead BE, Tong Z, Li Y, et al. Culturing human intestinal stem
616 cells for regenerative applications in the treatment of inflammatory bowel disease. *EMBO Mol
617 Med.* 2017;9:558–70. doi:10.15252/emmm.201607260.
- 618 5. Mclroy J, Ianiro G, Mukhopadhyaya I, Hansen R, Hold GL. Review article: the gut microbiome
619 in inflammatory bowel disease-avenues for microbial management. *Aliment Pharmacol Ther.*
620 2018;47:26–42. doi:10.1111/apt.14384.
- 621 6. Øyri SF, Múzes G, Sipos F. Dysbiotic gut microbiome: A key element of Crohn's disease.
622 *Comp Immunol Microbiol Infect Dis.* 2015;43:36–49.
- 623 7. Häsler R, Sheibani-Tezerji R, Sinha A, Barann M, Rehman A, Esser D, et al. Uncoupling of
624 mucosal gene regulation, mRNA splicing and adherent microbiota signatures in inflammatory
625 bowel disease. *Gut.* 2016;;gutjnl-2016-311651. doi:10.1136/gutjnl-2016-311651.

- 626 8. Haberman Y, Tickle TL, Dexheimer PJ, Kim M-O, Tang D, Karns R, et al. Pediatric Crohn
627 disease patients exhibit specific ileal transcriptome and microbiome signature. *J Clin Invest.*
628 2014;124:3617–33. doi:10.1172/JCI75436.
- 629 9. Loganathan P, Catinella AP, Hashash JG, Gajendran M, Loganathan P, Catinella AP, et al. A
630 comprehensive review and update on Crohn’s disease. *Dis Mon.* 2018;64:20–57.
631 <http://www.ncbi.nlm.nih.gov/pubmed/28826742>
632 <http://linkinghub.elsevier.com/retrieve/pii/S0011502917301530> [https://www-sciencedirect-](https://www-sciencedirect-com.sire.ub.edu/science/article/pii/S0011502917301530?via%3Dihub)
633 [com.sire.ub.edu/science/article/pii/S0011502917301530?via%3Dihub](https://www-sciencedirect-com.sire.ub.edu/science/article/pii/S0011502917301530?via%3Dihub).
- 634 10. Azimi T, Nasiri MJ, Chirani AS, Pouriran R, Dabiri H. The role of bacteria in the inflammatory
635 bowel disease development: a narrative review. *APMIS.* 2018;126:275–83.
- 636 11. Hata K, Ishihara S, Nozawa H, Kawai K, Kiyomatsu T, Tanaka T, et al. Pouchitis after ileal
637 pouch-anal anastomosis in ulcerative colitis: Diagnosis, management, risk factors, and
638 incidence. *Dig Endosc Off J Jpn Gastroenterol Endosc Soc.* 2017;29:26–34.
- 639 12. De Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: An integrated view of
640 aetiology, pathogenesis and therapy. Nature Publishing Group; 2017.
641 doi:10.1038/nrgastro.2017.110.
- 642 13. Gaujoux R, Starosvetsky E, Maimon N, Vallania F, Bar-Yoseph H, Pressman S, et al.
643 Inflammatory bowel disease Cell-centred meta-analysis reveals baseline predictors of anti-
644 TNF α non-response in biopsy and blood of patients with IBD. *Gut.* 2018;0:1–11.
645 doi:10.1136/gutjnl-2017-315494.
- 646 14. Huang H, Vangay P, McKinlay CE, Knights D. Multi-omics analysis of inflammatory bowel
647 disease. *Immunol Lett.* 2014;162:62–68. doi:10.1016/J.IMLET.2014.07.014.
- 648 15. Corraliza AM, Ricart E, López-García A, Carme Masamunt M, Veny M, Esteller M, et al.
649 Differences in Peripheral and Tissue Immune Cell Populations Following Haematopoietic Stem
650 Cell Transplantation in Crohn’s Disease Patients. *J Crohns Colitis.* doi:10.1093/ecco-jcc/jjy203.
- 651 16. Tang MS, Bowcutt R, Leung JM, Wolff MJ, Gundra UM, Hudesman D, et al. Integrated
652 Analysis of Biopsies from Inflammatory Bowel Disease Patients Identifies SAA1 as a Link
653 Between Mucosal Microbes with TH17 and TH22 Cells. *Inflamm Bowel Dis.* 2017;23:1544–54.
654 doi:10.1097/MIB.0000000000001208.
- 655 17. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, et al. The
656 Treatment-Naive Microbiome in New-Onset Crohn’s Disease. *Cell Host Microbe.* 2014;15:382–
657 92. doi:10.1016/j.chom.2014.02.005.
- 658 18. Presley LL, Ye J, Li X, LeBlanc J, Zhang Z, Ruegger PM, et al. Host-Microbe Relationships in
659 Inflammatory Bowel Disease Detected by Bacterial and Metaproteomic Analysis of the
660 Mucosal-Luminal Interface. *Inflamm Bowel Dis.* 2012;18:409–17. doi:10.1002/ibd.21793.
- 661 19. Lopez-Siles M, Enrich-Capó N, Aldeguer X, Sabat-Mir M, Duncan SH, Garcia-Gil LJ, et al.
662 Alterations in the Abundance and Co-occurrence of *Akkermansia muciniphila* and
663 *Faecalibacterium prausnitzii* in the Colonic Mucosa of Inflammatory Bowel Disease Subjects.
664 *Front Cell Infect Microbiol.* 2018;8. doi:10.3389/fcimb.2018.00281.

- 665 20. Saccenti E, Hoefsloot HCJ, Smilde AK, Westerhuis JA, Hendriks MMWB. Reflections on
666 univariate and multivariate analysis of metabolomics data. *Metabolomics*. 2014;10:361–74.
667 doi:10.1007/s11306-013-0598-6.
- 668 21. Lovell D, Pawlowsky-Glahn V, Egozcue JJ, Marguerat S, Bähler J. Proportionality: A Valid
669 Alternative to Correlation for Relative Data. *PLOS Comput Biol*. 2015;11:e1004075.
670 doi:10.1371/journal.pcbi.1004075.
- 671 22. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic
672 biomarker discovery and explanation. *Genome Biol*. 2011;12:R60. doi:10.1186/gb-2011-12-6-
673 r60.
- 674 23. Rohart F, Gautier B, Singh A, Cao K-AL. mixOmics: An R package for ‘omics feature selection
675 and multiple data integration. *PLOS Comput Biol*. 2017;13:e1005752.
676 doi:10.1371/journal.pcbi.1005752.
- 677 24. Deun KV, Mechelen IV, Thorrez L, Schouteden M, Moor BD, Werf MJ van der, et al. DISCO-
678 SCA and Properly Applied GSVD as Swinging Methods to Find Common and Distinctive
679 Processes. *PLOS ONE*. 2012;7:e37840. doi:10.1371/journal.pone.0037840.
- 680 25. Lock EF, Hoadley KA, Marron JS, Nobel AB. Joint and individual variation explained (JIVE) for
681 integrated analysis of multiple data types. *Ann Appl Stat*. 2013;7:523–42. doi:10.1214/12-
682 AOAS597.
- 683 26. Meng C, Kuster B, Culhane AC, Gholami AM. A multivariate approach to the integration of
684 multi-omics datasets. *BMC Bioinformatics*. 2014;15:162. doi:10.1186/1471-2105-15-162.
- 685 27. Witten DM, Tibshirani R, Hastie T. A penalized matrix decomposition, with applications to
686 sparse principal components and canonical correlation analysis. *Biostatistics*. 2009;10:515–34.
687 doi:10.1093/biostatistics/kxp008.
- 688 28. Tenenhaus A, Tenenhaus M. Regularized generalized canonical correlation analysis for
689 multiblock or multigroup data analysis. *Eur J Oper Res*. 2014;238:391–403.
690 doi:10.1016/j.ejor.2014.01.008.
- 691 29. Tenenhaus A, Tenenhaus M. Regularized Generalized Canonical Correlation Analysis.
692 *Psychometrika*. 2011;76:257–284. doi:10.1007/s11336-011-9206-8.
- 693 30. Löfstedt T, Hadj-Selem F, Guillemot V, Philippe C, Raymond N, Duchesney E, et al. A general
694 multiblock method for structured variable selection. *ArXiv161009490 Stat*. 2016.
695 <http://arxiv.org/abs/1610.09490>. Accessed 29 Jun 2018.
- 696 31. Puget S, Philippe C, Bax DA, Job B, Varlet P, Junier M-P, et al. Mesenchymal Transition and
697 PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic
698 Pontine Gliomas. *PLOS ONE*. 2012;7:e30313. doi:10.1371/journal.pone.0030313.
- 699 32. Morgan XC, Kabakchiev B, Waldron L, Tyler AD, Tickle TL, Milgrom R, et al. Associations
700 between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic
701 pouch of patients with inflammatory bowel disease. *Genome Biol*. 2015;16:67.
702 doi:10.1186/s13059-015-0637-x.

- 703 33. Lagkouvardos I, Kläring K, Heinzmann SS, Platz S, Scholz B, Engel K-H, et al. Gut metabolites
704 and bacterial community networks during a pilot intervention study with flaxseeds in healthy
705 adult men. *Mol Nutr Food Res*. 2015;59:1614–28. doi:10.1002/mnfr.201500125.
- 706 34. Berry D, Ben Mahfoudh K, Wagner M, Loy A. Barcoded primers used in multiplex amplicon
707 pyrosequencing bias amplification. *Appl Environ Microbiol*. 2011;77:7846–9.
- 708 35. Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, et al. Evaluation of general
709 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based
710 diversity studies. *Nucleic Acids Res*. 2013;41:e1–e1. doi:10.1093/nar/gks808.
- 711 36. Lagkouvardos I, Joseph D, Kapfhammer M, Giritli S, Horn M, Haller D, et al. IMNGS: A
712 comprehensive open resource of processed 16S rRNA microbial profiles for ecology and
713 diversity studies. *Sci Rep*. 2016;6. doi:10.1038/srep33721.
- 714 37. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. *Nat*
715 *Methods*. 2013;10:996–8. doi:10.1038/nmeth.2604.
- 716 38. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naïve Bayesian Classifier for Rapid Assignment of
717 rRNA Sequences into the New Bacterial Taxonomy. *Appl Environ Microbiol*. 2007;73:5261–7.
718 doi:10.1128/AEM.00062-07.
- 719 39. Sparse Generalized Canonical Correlation Analysis. <http://biodev.cea.fr/sgcca/>. Accessed
720 26 Sep 2018.
- 721 40. Tenenhaus A, Philippe C, Guillemot V, Le Cao K-A, Grill J, Frouin V. Variable selection for
722 generalized canonical correlation analysis. *Biostatistics*. 2014;15:569–83.
723 doi:10.1093/biostatistics/kxu001.
- 724 41. Schäfer J, Strimmer K. A Shrinkage Approach to Large-Scale Covariance Matrix Estimation
725 and Implications for Functional Genomics. *Stat Appl Genet Mol Biol*. 2005;4. doi:10.2202/1544-
726 6115.1175.
- 727 42. Tenenhaus M, Tenenhaus A, Groenen PJF. Regularized Generalized Canonical Correlation
728 Analysis: A Framework for Sequential Multiblock Component Methods. *Psychometrika*.
729 2017;82:737–77. doi:10.1007/s11336-017-9573-x.
- 730 43. Aleman FDD, Valenzano DR. Microbiome evolution during host aging. *PLOS Pathog*.
731 2019;15:e1007727. doi:10.1371/journal.ppat.1007727.
- 732 44. Schirmer M, Franzosa EA, Lloyd-Price J, McIver LJ, Schwager R, Poon TW, et al. Dynamics of
733 metatranscription in the inflammatory bowel disease gut microbiome. *Nat Microbiol*.
734 2018;3:337–346. doi:10.1038/s41564-017-0089-z.
- 735 45. Stubbendieck RM, Vargas-Bautista C, Straight PD. Bacterial Communities: Interactions to
736 Scale. *Front Microbiol*. 2016;7. doi:10.3389/fmicb.2016.01234.
- 737 46. Koren O, Knights D, Gonzalez A, Waldron L, Segata N, Knight R, et al. A Guide to
738 Enterotypes across the Human Body: Meta-Analysis of Microbial Community Structures in
739 Human Microbiome Datasets. *PLOS Comput Biol*. 2013;9:e1002863.
740 doi:10.1371/journal.pcbi.1002863.

741